Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086122 | 0.97 | TAS1R3 (0.39) | FAPTAS1R3TAS1R1ADORA1ADORA3 | |
| SCHEMBL5082373 | 0.85 | FAP (0.51) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5082477 | 0.83 | FAP (0.39) | FAPCYP1A2CYP3A4CYP2D6NT5E | |
| SCHEMBL5086442 | 0.81 | TAS1R3 (0.42) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5082989 | 0.78 | FAP (0.51) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5080075 | 0.77 | FAP (0.50) | FAPCYP3A4CYP2D6 | |
| SCHEMBL5086064 | 0.76 | TAS1R3 (0.38) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5083644 | 0.73 | ADORA1 (0.41) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5083566 | 0.73 | TAS1R3 (0.42) | TAS1R3TAS1R1ADORA1ADORA3ADORA2A | |
| SCHEMBL5083667 | 0.72 | P2RY1 (0.33) | ADORA1ADORA3CYP3A4CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | FAP 4556/4885TAS1R3 3404/4885TAS1R1 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.